APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Non-oncology Biopharmaceuticals

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Non-oncology Biopharmaceuticals Industry Growth and Trends Forecast to 2032

Report ID 174017660120 December 2025124 pages

Choose your research edition.

Industry ResearchNon-oncology Biopharmaceuticals Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-oncology Biopharmaceuticals Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Non-oncology Biopharmaceuticals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-oncology Biopharmaceuticals Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-oncology Biopharmaceuticals Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

According to APO Research, the global Non-oncology Biopharmaceuticals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Non-oncology Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Non-oncology Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-oncology Biopharmaceuticals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Non-oncology Biopharmaceuticals market include Takeda, Teva, Sanofi, Johnson & Johnson, Novartis, Novo Nordisk, Merck, Mylan and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Non-oncology Biopharmaceuticals market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Non-oncology Biopharmaceuticals market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Non-oncology Biopharmaceuticals market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Non-oncology Biopharmaceuticals.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Non-oncology Biopharmaceuticals market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Non-oncology Biopharmaceuticals Market by Company

Takeda

Teva

Sanofi

Johnson & Johnson

Novartis

Novo Nordisk

Merck

Mylan

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Biogen

Amgen

AbbVie

AstraZeneca

UCB Pharma

Swedish Orphan Biovitrum

LEO Pharma

Elusys Therapeutics

Bristol-Myers Squibb

Boehringer Ingelheim

Alexion Pharmaceuticals

Non-oncology Biopharmaceuticals Segment by Type

Biologics

Biosimilars

Non-oncology Biopharmaceuticals Segment by Application

Immunology

Endocrinology

Others

Non-oncology Biopharmaceuticals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-oncology Biopharmaceuticals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-oncology Biopharmaceuticals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-oncology Biopharmaceuticals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Non-oncology Biopharmaceuticals companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Non-oncology Biopharmaceuticals Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Non-oncology Biopharmaceuticals Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Non-oncology Biopharmaceuticals Market Share by Region (2021-2026) Table 4. Global Non-oncology Biopharmaceuticals Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Non-oncology Biopharmaceuticals Market Share by Region (2027-2032) Table 6. Global Non-oncology Biopharmaceuticals Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Non-oncology Biopharmaceuticals Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Non-oncology Biopharmaceuticals Market Size Share by Type (2021-2026) Table 9. Global Non-oncology Biopharmaceuticals Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Non-oncology Biopharmaceuticals Market Size Share Forecasted by Type (2027-2032) Table 11. North America Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Non-oncology Biopharmaceuticals Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Non-oncology Biopharmaceuticals Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Non-oncology Biopharmaceuticals Market Size Share by Application (2021-2026) Table 24. Global Non-oncology Biopharmaceuticals Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Non-oncology Biopharmaceuticals Market Size Share Forecasted by Application (2027-2032) Table 26. North America Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Non-oncology Biopharmaceuticals Industry Trends Table 37. Non-oncology Biopharmaceuticals Industry Drivers Table 38. Non-oncology Biopharmaceuticals Industry Opportunities and Challenges Table 39. Non-oncology Biopharmaceuticals Industry Restraints Table 40. Global Non-oncology Biopharmaceuticals Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Non-oncology Biopharmaceuticals Revenue Market Share by Company (2021-2026) Table 42. Global Non-oncology Biopharmaceuticals Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Non-oncology Biopharmaceuticals Key Company Headquarters & Area Served Table 44. Global Non-oncology Biopharmaceuticals Company, Product Type & Application Table 45. Global Non-oncology Biopharmaceuticals Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Non-oncology Biopharmaceuticals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Takeda Company Information Table 49. Takeda Business Overview Table 50. Takeda Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Takeda Non-oncology Biopharmaceuticals Product Portfolio Table 52. Takeda Recent Development Table 53. Teva Company Information Table 54. Teva Business Overview Table 55. Teva Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Teva Non-oncology Biopharmaceuticals Product Portfolio Table 57. Teva Recent Development Table 58. Sanofi Company Information Table 59. Sanofi Business Overview Table 60. Sanofi Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Sanofi Non-oncology Biopharmaceuticals Product Portfolio Table 62. Sanofi Recent Development Table 63. Johnson & Johnson Company Information Table 64. Johnson & Johnson Business Overview Table 65. Johnson & Johnson Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Johnson & Johnson Non-oncology Biopharmaceuticals Product Portfolio Table 67. Johnson & Johnson Recent Development Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Novartis Non-oncology Biopharmaceuticals Product Portfolio Table 72. Novartis Recent Development Table 73. Novo Nordisk Company Information Table 74. Novo Nordisk Business Overview Table 75. Novo Nordisk Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Novo Nordisk Non-oncology Biopharmaceuticals Product Portfolio Table 77. Novo Nordisk Recent Development Table 78. Merck Company Information Table 79. Merck Business Overview Table 80. Merck Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Merck Non-oncology Biopharmaceuticals Product Portfolio Table 82. Merck Recent Development Table 83. Mylan Company Information Table 84. Mylan Business Overview Table 85. Mylan Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Mylan Non-oncology Biopharmaceuticals Product Portfolio Table 87. Mylan Recent Development Table 88. Roche Company Information Table 89. Roche Business Overview Table 90. Roche Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Roche Non-oncology Biopharmaceuticals Product Portfolio Table 92. Roche Recent Development Table 93. Eli Lilly Company Information Table 94. Eli Lilly Business Overview Table 95. Eli Lilly Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Eli Lilly Non-oncology Biopharmaceuticals Product Portfolio Table 97. Eli Lilly Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Pfizer Non-oncology Biopharmaceuticals Product Portfolio Table 102. Pfizer Recent Development Table 103. GlaxoSmithKline Company Information Table 104. GlaxoSmithKline Business Overview Table 105. GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. GlaxoSmithKline Non-oncology Biopharmaceuticals Product Portfolio Table 107. GlaxoSmithKline Recent Development Table 108. Biogen Company Information Table 109. Biogen Business Overview Table 110. Biogen Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Biogen Non-oncology Biopharmaceuticals Product Portfolio Table 112. Biogen Recent Development Table 113. Amgen Company Information Table 114. Amgen Business Overview Table 115. Amgen Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Amgen Non-oncology Biopharmaceuticals Product Portfolio Table 117. Amgen Recent Development Table 118. AbbVie Company Information Table 119. AbbVie Business Overview Table 120. AbbVie Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. AbbVie Non-oncology Biopharmaceuticals Product Portfolio Table 122. AbbVie Recent Development Table 123. AstraZeneca Company Information Table 124. AstraZeneca Business Overview Table 125. AstraZeneca Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. AstraZeneca Non-oncology Biopharmaceuticals Product Portfolio Table 127. AstraZeneca Recent Development Table 128. UCB Pharma Company Information Table 129. UCB Pharma Business Overview Table 130. UCB Pharma Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. UCB Pharma Non-oncology Biopharmaceuticals Product Portfolio Table 132. UCB Pharma Recent Development Table 133. Swedish Orphan Biovitrum Company Information Table 134. Swedish Orphan Biovitrum Business Overview Table 135. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Portfolio Table 137. Swedish Orphan Biovitrum Recent Development Table 138. LEO Pharma Company Information Table 139. LEO Pharma Business Overview Table 140. LEO Pharma Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. LEO Pharma Non-oncology Biopharmaceuticals Product Portfolio Table 142. LEO Pharma Recent Development Table 143. Elusys Therapeutics Company Information Table 144. Elusys Therapeutics Business Overview Table 145. Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Elusys Therapeutics Non-oncology Biopharmaceuticals Product Portfolio Table 147. Elusys Therapeutics Recent Development Table 148. Bristol-Myers Squibb Company Information Table 149. Bristol-Myers Squibb Business Overview Table 150. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Portfolio Table 152. Bristol-Myers Squibb Recent Development Table 153. Boehringer Ingelheim Company Information Table 154. Boehringer Ingelheim Business Overview Table 155. Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 156. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Portfolio Table 157. Boehringer Ingelheim Recent Development Table 158. Alexion Pharmaceuticals Company Information Table 159. Alexion Pharmaceuticals Business Overview Table 160. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 161. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Portfolio Table 162. Alexion Pharmaceuticals Recent Development Table 163. North America Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. North America Non-oncology Biopharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 165. North America Non-oncology Biopharmaceuticals Market Share by Country (2021-2026) Table 166. North America Non-oncology Biopharmaceuticals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. North America Non-oncology Biopharmaceuticals Market Share Forecast by Country (2027-2032) Table 168. Europe Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Europe Non-oncology Biopharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 170. Europe Non-oncology Biopharmaceuticals Market Share by Country (2021-2026) Table 171. Europe Non-oncology Biopharmaceuticals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Europe Non-oncology Biopharmaceuticals Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 175. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Country (2021-2026) Table 176. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. Asia-Pacific Non-oncology Biopharmaceuticals Market Share Forecast by Country (2027-2032) Table 178. Latin America Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Latin America Non-oncology Biopharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 180. Latin America Non-oncology Biopharmaceuticals Market Share by Country (2021-2026) Table 181. Latin America Non-oncology Biopharmaceuticals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Latin America Non-oncology Biopharmaceuticals Market Share Forecast by Country (2027-2032) Table 183. Middle East & Africa Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2021-2026) & (US$ Million) Table 185. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Country (2021-2026) Table 186. Middle East & Africa Non-oncology Biopharmaceuticals Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. Middle East & Africa Non-oncology Biopharmaceuticals Market Share Forecast by Country (2027-2032) Table 188. Research Programs/Design for This Report Table 189. Authors List of This Report Table 190. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Non-oncology Biopharmaceuticals Product Image Figure 3. Global Non-oncology Biopharmaceuticals Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Non-oncology Biopharmaceuticals Market Size (2021-2032) & (US$ Million) Figure 5. Global Non-oncology Biopharmaceuticals Market Share by Region: 2025 VS 2032 Figure 6. Global Non-oncology Biopharmaceuticals Market Share by Region (2021-2032) Figure 7. North America Non-oncology Biopharmaceuticals Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Non-oncology Biopharmaceuticals Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Non-oncology Biopharmaceuticals Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Non-oncology Biopharmaceuticals Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Biologics Image Figure 13. Global Biologics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Biosimilars Image Figure 15. Global Biosimilars Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Non-oncology Biopharmaceuticals Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Non-oncology Biopharmaceuticals Market Share by Type 2025 VS 2032 Figure 18. North America Non-oncology Biopharmaceuticals Market Size Share by Type (2021-2032) Figure 19. Europe Non-oncology Biopharmaceuticals Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Share by Type (2021-2032) Figure 21. Latin America Non-oncology Biopharmaceuticals Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Non-oncology Biopharmaceuticals Market Size Share by Type (2021-2032) Figure 23. Immunology Image Figure 24. Global Immunology Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Endocrinology Image Figure 26. Global Endocrinology Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Others Image Figure 28. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global Non-oncology Biopharmaceuticals Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Non-oncology Biopharmaceuticals Market Share by Application 2025 VS 2032 Figure 31. North America Non-oncology Biopharmaceuticals Market Size Share by Application (2021-2032) Figure 32. Europe Non-oncology Biopharmaceuticals Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific Non-oncology Biopharmaceuticals Market Size Share by Application (2021-2032) Figure 34. Latin America Non-oncology Biopharmaceuticals Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa Non-oncology Biopharmaceuticals Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 Non-oncology Biopharmaceuticals Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America Non-oncology Biopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America Non-oncology Biopharmaceuticals Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America Non-oncology Biopharmaceuticals Market Share by Country (2021-2032) Figure 41. Europe Non-oncology Biopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe Non-oncology Biopharmaceuticals Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Non-oncology Biopharmaceuticals Market Share by Country (2021-2032) Figure 44. Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific Non-oncology Biopharmaceuticals Market Share by Country (2021-2032) Figure 47. Latin America Non-oncology Biopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America Non-oncology Biopharmaceuticals Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America Non-oncology Biopharmaceuticals Market Share by Country (2021-2032) Figure 50. Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa Non-oncology Biopharmaceuticals Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • Biologics
  • Biosimilars
Applications
  • Immunology
  • Endocrinology
  • Others
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Novo Nordisk
  • Merck
  • Mylan
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Amgen
  • AbbVie
  • AstraZeneca
  • UCB Pharma
  • Swedish Orphan Biovitrum
  • LEO Pharma
  • Elusys Therapeutics
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Alexion Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Non-oncology Biopharmaceuticals Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Non-oncology Biopharmaceuticals Market Size by Region (2021-2032)
  5. 1.4.1 Global Non-oncology Biopharmaceuticals Market Size by Region (2021-2026)
  6. 1.4.2 Global Non-oncology Biopharmaceuticals Market Size by Region (2027-2032)
  7. 1.5 Key Regions Non-oncology Biopharmaceuticals Market Size (2021-2032)
  8. 1.5.1 North America Non-oncology Biopharmaceuticals Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Non-oncology Biopharmaceuticals Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Non-oncology Biopharmaceuticals Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Non-oncology Biopharmaceuticals Market Size Growth Rate (2021-2032)
2 Non-oncology Biopharmaceuticals Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Biologics
  3. 2.1.2 Biosimilars
  4. 2.2 Global Non-oncology Biopharmaceuticals Market Size by Type
  5. 2.2.1 Global Non-oncology Biopharmaceuticals Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Non-oncology Biopharmaceuticals Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Non-oncology Biopharmaceuticals Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Non-oncology Biopharmaceuticals Market Size by Regions
  9. 2.3.1 North America Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Non-oncology Biopharmaceuticals Market Size Breakdown by Type (2021-2026)
3 Non-oncology Biopharmaceuticals Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Immunology
  3. 3.1.2 Endocrinology
  4. 3.1.3 Others
  5. 3.2 Global Non-oncology Biopharmaceuticals Market Size by Application
  6. 3.2.1 Global Non-oncology Biopharmaceuticals Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Non-oncology Biopharmaceuticals Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Non-oncology Biopharmaceuticals Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Non-oncology Biopharmaceuticals Market Size by Regions
  10. 3.3.1 North America Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Non-oncology Biopharmaceuticals Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Non-oncology Biopharmaceuticals Industry Trends
  2. 4.2 Non-oncology Biopharmaceuticals Industry Drivers
  3. 4.3 Non-oncology Biopharmaceuticals Industry Opportunities and Challenges
  4. 4.4 Non-oncology Biopharmaceuticals Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Non-oncology Biopharmaceuticals Revenue (2021-2026)
  2. 5.2 Global Non-oncology Biopharmaceuticals Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Non-oncology Biopharmaceuticals Key Company Headquarters & Area Served
  4. 5.4 Global Non-oncology Biopharmaceuticals Company, Product Type & Application
  5. 5.5 Global Non-oncology Biopharmaceuticals Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Non-oncology Biopharmaceuticals Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Non-oncology Biopharmaceuticals Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Non-oncology Biopharmaceuticals Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Takeda
  2. 6.1.1 Takeda Company Information
  3. 6.1.2 Takeda Business Overview
  4. 6.1.3 Takeda Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Non-oncology Biopharmaceuticals Product Portfolio
  6. 6.1.5 Takeda Recent Developments
  7. 6.2 Teva
  8. 6.2.1 Teva Company Information
  9. 6.2.2 Teva Business Overview
  10. 6.2.3 Teva Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Teva Non-oncology Biopharmaceuticals Product Portfolio
  12. 6.2.5 Teva Recent Developments
  13. 6.3 Sanofi
  14. 6.3.1 Sanofi Company Information
  15. 6.3.2 Sanofi Business Overview
  16. 6.3.3 Sanofi Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Sanofi Non-oncology Biopharmaceuticals Product Portfolio
  18. 6.3.5 Sanofi Recent Developments
  19. 6.4 Johnson & Johnson
  20. 6.4.1 Johnson & Johnson Company Information
  21. 6.4.2 Johnson & Johnson Business Overview
  22. 6.4.3 Johnson & Johnson Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Johnson & Johnson Non-oncology Biopharmaceuticals Product Portfolio
  24. 6.4.5 Johnson & Johnson Recent Developments
  25. 6.5 Novartis
  26. 6.5.1 Novartis Company Information
  27. 6.5.2 Novartis Business Overview
  28. 6.5.3 Novartis Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Novartis Non-oncology Biopharmaceuticals Product Portfolio
  30. 6.5.5 Novartis Recent Developments
  31. 6.6 Novo Nordisk
  32. 6.6.1 Novo Nordisk Company Information
  33. 6.6.2 Novo Nordisk Business Overview
  34. 6.6.3 Novo Nordisk Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Novo Nordisk Non-oncology Biopharmaceuticals Product Portfolio
  36. 6.6.5 Novo Nordisk Recent Developments
  37. 6.7 Merck
  38. 6.7.1 Merck Company Information
  39. 6.7.2 Merck Business Overview
  40. 6.7.3 Merck Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Merck Non-oncology Biopharmaceuticals Product Portfolio
  42. 6.7.5 Merck Recent Developments
  43. 6.8 Mylan
  44. 6.8.1 Mylan Company Information
  45. 6.8.2 Mylan Business Overview
  46. 6.8.3 Mylan Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Mylan Non-oncology Biopharmaceuticals Product Portfolio
  48. 6.8.5 Mylan Recent Developments
  49. 6.9 Roche
  50. 6.9.1 Roche Company Information
  51. 6.9.2 Roche Business Overview
  52. 6.9.3 Roche Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Roche Non-oncology Biopharmaceuticals Product Portfolio
  54. 6.9.5 Roche Recent Developments
  55. 6.10 Eli Lilly
  56. 6.10.1 Eli Lilly Company Information
  57. 6.10.2 Eli Lilly Business Overview
  58. 6.10.3 Eli Lilly Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Eli Lilly Non-oncology Biopharmaceuticals Product Portfolio
  60. 6.10.5 Eli Lilly Recent Developments
  61. 6.11 Pfizer
  62. 6.11.1 Pfizer Company Information
  63. 6.11.2 Pfizer Business Overview
  64. 6.11.3 Pfizer Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Pfizer Non-oncology Biopharmaceuticals Product Portfolio
  66. 6.11.5 Pfizer Recent Developments
  67. 6.12 GlaxoSmithKline
  68. 6.12.1 GlaxoSmithKline Company Information
  69. 6.12.2 GlaxoSmithKline Business Overview
  70. 6.12.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 GlaxoSmithKline Non-oncology Biopharmaceuticals Product Portfolio
  72. 6.12.5 GlaxoSmithKline Recent Developments
  73. 6.13 Biogen
  74. 6.13.1 Biogen Company Information
  75. 6.13.2 Biogen Business Overview
  76. 6.13.3 Biogen Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Biogen Non-oncology Biopharmaceuticals Product Portfolio
  78. 6.13.5 Biogen Recent Developments
  79. 6.14 Amgen
  80. 6.14.1 Amgen Company Information
  81. 6.14.2 Amgen Business Overview
  82. 6.14.3 Amgen Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Amgen Non-oncology Biopharmaceuticals Product Portfolio
  84. 6.14.5 Amgen Recent Developments
  85. 6.15 AbbVie
  86. 6.15.1 AbbVie Company Information
  87. 6.15.2 AbbVie Business Overview
  88. 6.15.3 AbbVie Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 AbbVie Non-oncology Biopharmaceuticals Product Portfolio
  90. 6.15.5 AbbVie Recent Developments
  91. 6.16 AstraZeneca
  92. 6.16.1 AstraZeneca Company Information
  93. 6.16.2 AstraZeneca Business Overview
  94. 6.16.3 AstraZeneca Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 AstraZeneca Non-oncology Biopharmaceuticals Product Portfolio
  96. 6.16.5 AstraZeneca Recent Developments
  97. 6.17 UCB Pharma
  98. 6.17.1 UCB Pharma Company Information
  99. 6.17.2 UCB Pharma Business Overview
  100. 6.17.3 UCB Pharma Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 UCB Pharma Non-oncology Biopharmaceuticals Product Portfolio
  102. 6.17.5 UCB Pharma Recent Developments
  103. 6.18 Swedish Orphan Biovitrum
  104. 6.18.1 Swedish Orphan Biovitrum Company Information
  105. 6.18.2 Swedish Orphan Biovitrum Business Overview
  106. 6.18.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product Portfolio
  108. 6.18.5 Swedish Orphan Biovitrum Recent Developments
  109. 6.19 LEO Pharma
  110. 6.19.1 LEO Pharma Company Information
  111. 6.19.2 LEO Pharma Business Overview
  112. 6.19.3 LEO Pharma Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 LEO Pharma Non-oncology Biopharmaceuticals Product Portfolio
  114. 6.19.5 LEO Pharma Recent Developments
  115. 6.20 Elusys Therapeutics
  116. 6.20.1 Elusys Therapeutics Company Information
  117. 6.20.2 Elusys Therapeutics Business Overview
  118. 6.20.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Elusys Therapeutics Non-oncology Biopharmaceuticals Product Portfolio
  120. 6.20.5 Elusys Therapeutics Recent Developments
  121. 6.21 Bristol-Myers Squibb
  122. 6.21.1 Bristol-Myers Squibb Company Information
  123. 6.21.2 Bristol-Myers Squibb Business Overview
  124. 6.21.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product Portfolio
  126. 6.21.5 Bristol-Myers Squibb Recent Developments
  127. 6.22 Boehringer Ingelheim
  128. 6.22.1 Boehringer Ingelheim Company Information
  129. 6.22.2 Boehringer Ingelheim Business Overview
  130. 6.22.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  131. 6.22.4 Boehringer Ingelheim Non-oncology Biopharmaceuticals Product Portfolio
  132. 6.22.5 Boehringer Ingelheim Recent Developments
  133. 6.23 Alexion Pharmaceuticals
  134. 6.23.1 Alexion Pharmaceuticals Company Information
  135. 6.23.2 Alexion Pharmaceuticals Business Overview
  136. 6.23.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue, Global Share and Gross Margin (2021-2026)
  137. 6.23.4 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product Portfolio
  138. 6.23.5 Alexion Pharmaceuticals Recent Developments
7 North America
  1. 7.1 North America Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Non-oncology Biopharmaceuticals Market Size by Country (2021-2026)
  3. 7.3 North America Non-oncology Biopharmaceuticals Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Non-oncology Biopharmaceuticals Market Size by Country (2021-2026)
  3. 8.3 Europe Non-oncology Biopharmaceuticals Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Non-oncology Biopharmaceuticals Market Size by Country (2021-2026)
  3. 10.3 South America Non-oncology Biopharmaceuticals Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Non-oncology Biopharmaceuticals Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst